RESULTS OF OBSERVATIONAL PROGRAM ON USE OF INSULIN GLARGINE (LANTUS®) IN COMBINATION WITH ORAL HYPOGLYCEMIC AGENTS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN ROUTINE CLINICAL PRACTICE


如何引用文章

全文:

详细

The article presents the results of observational program on the use of insulin glargine in clinical practice foe the treatment of patients with type 2 diabetes mellitus (DM2) inadequately controlled on monotherapy with metformin or sulfonylurea. The program included 2500 patients. Addition of insulin glargine to metformin/sulfonylurea monotherapy resulted in improvement of glycemic control in patients with DM2 (reduction of average glycated hemoglobin level by 2,1 %, and fasting plasma glucose - by 4,4 mg/dL. Hypoglycemic episodes within 3 months after initiation of insulin glargine therapy have been reported in 17 % of patients, most of them have experienced only 1-2 episodes. Body weight did not increase in these patients.

参考

  1. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
  2. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
  3. Nathan D, Buse JB, Davidson MB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 2009;32(1):193-203.
  4. Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006;37:495-501.
  5. Fritsche A, Schweitzer MA, Häring H-U; 4001 study group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-59.
  6. Massi Benedetti MM, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-96.
  7. Pan C-Y, Sinnassamy P, Chung K-D, et al. LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res Clin Pract 2007;76:111-18.
  8. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-86.
  9. Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-36.
  10. Yki-Järvinen, Dressler A, Ziemen M; HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-36.
  11. Dixon S, Peters JR. Evaluating the 'real' cost-effectiveness of health technology: reconciling the public interest with patients' interests. Curr Med Res Opin 2007;23(Suppl. 1):S1-S6.
  12. Davies M, Storms F, Shutler S, et al, AT.LANTUS study group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-88.
  13. Monnier L, Lapinski H, Collette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA1C. Diabetes Care 2003;26:881-85.
  14. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
  15. Skyler S, Bergenstal R, Bonow R, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials // Diabetes Care 2009;32(1):187-92.
  16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой. М., 2009. 104 c.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##